An Albuquerque biotech company says patients can use its technology to deliver medication to patients' respiratory system with hardly any effort.
The startup, Nob Hill Therapeutics, is aiming to commercialize a nebulizer that disaggregates powdered particles, spreading them out. Doing so makes it easier for patients to use the medication with a more efficient delivery, according to executive chairman Paul Atkins. The technology has a "wide variety of potential opportunities," Atkins told Business First.
The technology was developed at the University of New Mexico before being licensed by Nob Hill Therapeutics, which is part of the VIC Technology Venture Development, a technology commercialization organization. The startup is led by CEO Yun Li, who is director of VIC's New Mexico branch, plus Atkins, chief scientific officer Matt Reed and chief technology officer Hugh Smyth.
Normal breathing levels can deliver a high dose of medication as opposed to large breaths, Li said. While its main product currently focuses on pulmonary aspergillosis, a fungal infection caused by mold, its nebulizer can also be used to address viral and bacterial infections, according to its website.
Nob Hill Therapeutics is seeking to raise $5 million for clinical-phase research. The New Mexico Angels recently hosted a pitch event for the company, which Atkins said is looking for institutional investors.
The startup was founded in 2017, and the company is located at the BioScience Center on Indian School Road, its website says. It is also one of just six organizations spun with tech from the University of New Mexico between July 1, 2020, and June 30 of this year, according to a report from UNM's Rainforest Innovations.
Rainforest Innovations aims to foster economic development and transfer tech developed at UNM to the market.
